US 11,981,893 B2
DNA stabilization of RNA
Patrick Soon-Shiong, Culver City, CA (US); Shahrooz Rabizadeh, Agoura Hills, CA (US); and Kathleen Danenberg, Altadena, CA (US)
Assigned to Nantomics LLC, Culver City, CA (US)
Filed by Nantomics, Culver City, CA (US)
Filed on Oct. 4, 2021, as Appl. No. 17/493,637.
Application 17/493,637 is a division of application No. 16/618,017, granted, now 11,168,323, previously published as PCT/US2018/035123, filed on May 30, 2018.
Claims priority of provisional application 62/513,947, filed on Jun. 1, 2017.
Prior Publication US 2022/0025362 A1, Jan. 27, 2022
Int. Cl. C12N 15/11 (2006.01); C12N 15/10 (2006.01); C12Q 1/6876 (2018.01)
CPC C12N 15/11 (2013.01) [C12N 15/1003 (2013.01); C12Q 1/6876 (2013.01); C12N 2320/51 (2013.01); C12Q 2565/00 (2013.01)] 12 Claims
 
1. A method of collecting cfRNA in blood, the method comprising introducing the blood into a collection tube that contains, before or after the introduction of the blood, at least one of (a) exogenous DNA in an amount of between 1-100 micrograms per 10 mL of blood and (b) a DNaseI inhibitor at a concentration of 10-1,000 microgram/ml, and wherein the exogenous DNA is human DNA or salmon sperm DNA, comprising removing cells from the blood, contacting a solid carrier with the cfRNA and exogenous DNA to adsorb the cfRNA onto the solid carrier, and eluting the cfRNA from the carrier under conditions that separates the eluted RNA from exogenous DNA.